Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075624608> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2075624608 endingPage "973" @default.
- W2075624608 startingPage "973" @default.
- W2075624608 abstract "The aim of our study was to assess the role of rituximab (Mabthera) in the treatment of patients with corticosteroid-resistant and calcineurin-inhibitors ± cellcept refractory idiopathic nephrotic syndrome (INS). A total of 83 patients who had required the previous treatment for a minimum of two years were included in the study. Our protocol included the use of rituximab in four-weekly slow infusions. Five patients were excluded as they could not tolerate rituximab infusion for allergic reaction. As expected, none of the patients had a decline in the total circulating lymphocyte counts yet all had achieved decline of their initially normal CD20 to < 0.5% one month after infusion. The decline persisted for eight to ten months later. In the minimal change disease (MCD) group, 31 of the 32 patients had complete remission (CR) and were off any immunosuppressive therapy and one of the previous non-responders (NR) did not respond. Excluding two patients who had required retreatment, the others remained in CR (17 up to 28 months and six up to 36 months). Treatment with rituximab resulted in amelioration of NS in 17 of the 18 patients with focal segmental glomerulosclerosis (FSGS), while only one patient remained NR. Although renal function remained stable, proteinuria reappeared by eight to 12 months. Retreatment with rituximab resulted in a similar response with stable kidney function. In the 28 patients with membranous glomerulopathy (MG), 24 had achieved CR. Two patients failed to respond and two had partial remission. By 12 months, all patients relapsed. The response was within one month following treatment in patient with MCD, but was gradual within three months in FSGS and MG. Relapsers in all groups responded in a similar pattern to repeat dosing with the drug subsequently. Our prospective study represents an adequate number of patients with biopsy-proven subgroups of INS in both children and adults with long-term follow-up of treatment with rituximab. The drug is effective and safe for treatment of patients refractory to the conventional agents." @default.
- W2075624608 created "2016-06-24" @default.
- W2075624608 creator A5007375186 @default.
- W2075624608 creator A5047185665 @default.
- W2075624608 creator A5052793800 @default.
- W2075624608 creator A5085699340 @default.
- W2075624608 date "2012-01-01" @default.
- W2075624608 modified "2023-10-01" @default.
- W2075624608 title "Rituximab in treatment of idiopathic glomerulopathy" @default.
- W2075624608 doi "https://doi.org/10.4103/1319-2442.100878" @default.
- W2075624608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22982909" @default.
- W2075624608 hasPublicationYear "2012" @default.
- W2075624608 type Work @default.
- W2075624608 sameAs 2075624608 @default.
- W2075624608 citedByCount "13" @default.
- W2075624608 countsByYear W20756246082013 @default.
- W2075624608 countsByYear W20756246082014 @default.
- W2075624608 countsByYear W20756246082016 @default.
- W2075624608 countsByYear W20756246082017 @default.
- W2075624608 countsByYear W20756246082018 @default.
- W2075624608 countsByYear W20756246082020 @default.
- W2075624608 countsByYear W20756246082022 @default.
- W2075624608 countsByYear W20756246082023 @default.
- W2075624608 crossrefType "journal-article" @default.
- W2075624608 hasAuthorship W2075624608A5007375186 @default.
- W2075624608 hasAuthorship W2075624608A5047185665 @default.
- W2075624608 hasAuthorship W2075624608A5052793800 @default.
- W2075624608 hasAuthorship W2075624608A5085699340 @default.
- W2075624608 hasBestOaLocation W20756246081 @default.
- W2075624608 hasConcept C121332964 @default.
- W2075624608 hasConcept C126322002 @default.
- W2075624608 hasConcept C126894567 @default.
- W2075624608 hasConcept C141071460 @default.
- W2075624608 hasConcept C142424586 @default.
- W2075624608 hasConcept C159641895 @default.
- W2075624608 hasConcept C159654299 @default.
- W2075624608 hasConcept C203014093 @default.
- W2075624608 hasConcept C2778415529 @default.
- W2075624608 hasConcept C2778842783 @default.
- W2075624608 hasConcept C2778930706 @default.
- W2075624608 hasConcept C2779338263 @default.
- W2075624608 hasConcept C2779561371 @default.
- W2075624608 hasConcept C2780091579 @default.
- W2075624608 hasConcept C2780199430 @default.
- W2075624608 hasConcept C2780653079 @default.
- W2075624608 hasConcept C71924100 @default.
- W2075624608 hasConcept C87355193 @default.
- W2075624608 hasConcept C90924648 @default.
- W2075624608 hasConceptScore W2075624608C121332964 @default.
- W2075624608 hasConceptScore W2075624608C126322002 @default.
- W2075624608 hasConceptScore W2075624608C126894567 @default.
- W2075624608 hasConceptScore W2075624608C141071460 @default.
- W2075624608 hasConceptScore W2075624608C142424586 @default.
- W2075624608 hasConceptScore W2075624608C159641895 @default.
- W2075624608 hasConceptScore W2075624608C159654299 @default.
- W2075624608 hasConceptScore W2075624608C203014093 @default.
- W2075624608 hasConceptScore W2075624608C2778415529 @default.
- W2075624608 hasConceptScore W2075624608C2778842783 @default.
- W2075624608 hasConceptScore W2075624608C2778930706 @default.
- W2075624608 hasConceptScore W2075624608C2779338263 @default.
- W2075624608 hasConceptScore W2075624608C2779561371 @default.
- W2075624608 hasConceptScore W2075624608C2780091579 @default.
- W2075624608 hasConceptScore W2075624608C2780199430 @default.
- W2075624608 hasConceptScore W2075624608C2780653079 @default.
- W2075624608 hasConceptScore W2075624608C71924100 @default.
- W2075624608 hasConceptScore W2075624608C87355193 @default.
- W2075624608 hasConceptScore W2075624608C90924648 @default.
- W2075624608 hasIssue "5" @default.
- W2075624608 hasLocation W20756246081 @default.
- W2075624608 hasLocation W20756246082 @default.
- W2075624608 hasLocation W20756246083 @default.
- W2075624608 hasOpenAccess W2075624608 @default.
- W2075624608 hasPrimaryLocation W20756246081 @default.
- W2075624608 hasRelatedWork W1964669350 @default.
- W2075624608 hasRelatedWork W1967712182 @default.
- W2075624608 hasRelatedWork W2015933223 @default.
- W2075624608 hasRelatedWork W2055656354 @default.
- W2075624608 hasRelatedWork W2068785804 @default.
- W2075624608 hasRelatedWork W2159732018 @default.
- W2075624608 hasRelatedWork W2474827085 @default.
- W2075624608 hasRelatedWork W2571795535 @default.
- W2075624608 hasRelatedWork W2623390040 @default.
- W2075624608 hasRelatedWork W3003424216 @default.
- W2075624608 hasVolume "23" @default.
- W2075624608 isParatext "false" @default.
- W2075624608 isRetracted "false" @default.
- W2075624608 magId "2075624608" @default.
- W2075624608 workType "article" @default.